Sanofi Reports the EC Approval of Rezurock (Belumosudil) to Treat Chronic Graft-vs-Host Disease (GVHD) 

Shots: 

• The EC has approved Rezurock (200mg) to treat chronic GVHD pts (≥12yrs., ≥40kg) 

• Approval was based on safety and efficacy clinical data, incl. the P-II (ROCKstar) trial (n=77), which showed an improved ORR of 74% in chronic GVHD pts post–stem cell transplant & after ≥2 prior systemic therapies 

• Under the conditional marketing authorisation, Sanofi will conduct a confirmatory randomized study

Ref: Sanofi |  Image: Sanofi  | Press Release

Related News: Sanofi Receives the CHMP Positive Opinion for Rezurock (Belumosudil) to Treat Chronic Graft-vs-Host Disease (GVHD)

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com